2025 Q4 -tulosraportti
21 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 72 | - | - | ||
| 6 250 | - | - | ||
| 185 | - | - | ||
| 76 243 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 214 715 | 3 214 715 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 214 715 | 3 214 715 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten · Muokattu@Micketro (Krosen on Placera-forum) If Jeff achieves what he believes about March-April and that the 50 states are ready to receive the test, then we should see a short rally, right, before new financing challenges arise? Remember also that there will probably be a small share price boost perhaps just from the announcement that the application to Medicare has been submitted this summer. If they manage to hurry up and convince a partner to step a bit deeper before time. That could really be what we need with this stock. But such things are very uncertain regarding a partner.. Do you think they'll fix that with a bridge loan, or partnership? There's probably little point with a NE for such a small amount. Investors will surely flee if there are too many NEs in a row, those are my thoughts on it. I see you're commenting on a guessed amount: https://forum.placera.se/inlagg/1be7359a-7527-4edb-ad12-72992b3e89da
·21 t sitten · MuokattuI actually don't know how they will raise the money, even though NE is the only thing they have used historically. The post was just an estimate of how much money is missing when one accounts for carlsquares sales forecasts. Here one must assume that all sales in New York etc are already included. They need to raise 100 million before q4 this year if one trusts Carlsquares figures, if they are to make it to 2027
·13.3. · MuokattuAll-time low today. I have gone long in this stock with relatively small capital. It is either a stock that will be quickly revalued when it happens, because the product is good and needs to be established in the market. If this doesn't happen, I think it will be difficult for the company to survive.
·20 t sittenGood product, but low demand due to insufficient marketing.·11 t sittenI think it's the opposite, actually. They have invested heavily in close contact with many test centers, and have pushed hard on the marketing side. But the product itself is something that doesn't have an obvious place in a clinical workflow, and work is needed from the client side to figure out how to use it.- ·13.3.A little positive general treatment development, cancer treatment in Tromsø, Norway. Imagine if the headline was as one read it. Which it isn't. It is the radiation that is the radioactive missiles they are talking about, and not radioactive material from war materiel (my thoughts did go a bit to Iranian uranium, I must admit 🙈). https://www.nrk.no/tromsogfinnmark/forskere-ved-uit-og-unn-skal-bruke-_radioaktive-missiler_-mot-alvorlig-kreft-1.17804026 Subsequently, doctors can send a more powerful type of radioactive substance to the same cells. – We use a carrier molecule that recognizes special characteristics of cancer cells. It transports the radiation directly to them and kills the cancer cells without damaging the surrounding tissue, explains Sundset. The treatment is particularly aimed at patients where other forms of treatment no longer work. According to Sundset, cancer cells can eventually become resistant to treatments such as chemotherapy, radiation, and immunotherapy.
- ·13.3.Risk index predicts pancreatic neuroendocrine tumor recurrence Translated from Israeli Text is behind a registration wall (you who are medical personnel). Still a somewhat interesting headline https://www.e-med.co.il/specialties/oncology/2026/03/12/601301 Source: JAMA Surgery Prof. Amit Akirov 12/03/2026 No comments Risk index based on four factors – male gender, tumor size, grade according to the World Health Organization classification, and lymphovascular
- ·13.3.Does anyone know if Immunovia/ PancreaSure is involved in this great news from Piedmont? https://www.linkedin.com/posts/andrew-page-md-193622106_our-team-is-indebted-to-many-donors-and-supporters-activity-7435783495425126401-x-oc "Our team is indebted to many donors and supporters of the Surgical Oncology and HPB Program at Piedmont. Last week we were honored by a transformational gift to create the Sherron Berg Early Detection Pancreatic Cancer Program, and I am humbled to now be the Sherron Berg Medical Director. Our team will continue to work towards earlier detection and access to research - with the shared vision for more cures from pancreatic cancer."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
21 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · Muokattu@Micketro (Krosen on Placera-forum) If Jeff achieves what he believes about March-April and that the 50 states are ready to receive the test, then we should see a short rally, right, before new financing challenges arise? Remember also that there will probably be a small share price boost perhaps just from the announcement that the application to Medicare has been submitted this summer. If they manage to hurry up and convince a partner to step a bit deeper before time. That could really be what we need with this stock. But such things are very uncertain regarding a partner.. Do you think they'll fix that with a bridge loan, or partnership? There's probably little point with a NE for such a small amount. Investors will surely flee if there are too many NEs in a row, those are my thoughts on it. I see you're commenting on a guessed amount: https://forum.placera.se/inlagg/1be7359a-7527-4edb-ad12-72992b3e89da·21 t sitten · MuokattuI actually don't know how they will raise the money, even though NE is the only thing they have used historically. The post was just an estimate of how much money is missing when one accounts for carlsquares sales forecasts. Here one must assume that all sales in New York etc are already included. They need to raise 100 million before q4 this year if one trusts Carlsquares figures, if they are to make it to 2027
- ·13.3. · MuokattuAll-time low today. I have gone long in this stock with relatively small capital. It is either a stock that will be quickly revalued when it happens, because the product is good and needs to be established in the market. If this doesn't happen, I think it will be difficult for the company to survive.·20 t sittenGood product, but low demand due to insufficient marketing.·11 t sittenI think it's the opposite, actually. They have invested heavily in close contact with many test centers, and have pushed hard on the marketing side. But the product itself is something that doesn't have an obvious place in a clinical workflow, and work is needed from the client side to figure out how to use it.
- ·13.3.A little positive general treatment development, cancer treatment in Tromsø, Norway. Imagine if the headline was as one read it. Which it isn't. It is the radiation that is the radioactive missiles they are talking about, and not radioactive material from war materiel (my thoughts did go a bit to Iranian uranium, I must admit 🙈). https://www.nrk.no/tromsogfinnmark/forskere-ved-uit-og-unn-skal-bruke-_radioaktive-missiler_-mot-alvorlig-kreft-1.17804026 Subsequently, doctors can send a more powerful type of radioactive substance to the same cells. – We use a carrier molecule that recognizes special characteristics of cancer cells. It transports the radiation directly to them and kills the cancer cells without damaging the surrounding tissue, explains Sundset. The treatment is particularly aimed at patients where other forms of treatment no longer work. According to Sundset, cancer cells can eventually become resistant to treatments such as chemotherapy, radiation, and immunotherapy.
- ·13.3.Risk index predicts pancreatic neuroendocrine tumor recurrence Translated from Israeli Text is behind a registration wall (you who are medical personnel). Still a somewhat interesting headline https://www.e-med.co.il/specialties/oncology/2026/03/12/601301 Source: JAMA Surgery Prof. Amit Akirov 12/03/2026 No comments Risk index based on four factors – male gender, tumor size, grade according to the World Health Organization classification, and lymphovascular
- ·13.3.Does anyone know if Immunovia/ PancreaSure is involved in this great news from Piedmont? https://www.linkedin.com/posts/andrew-page-md-193622106_our-team-is-indebted-to-many-donors-and-supporters-activity-7435783495425126401-x-oc "Our team is indebted to many donors and supporters of the Surgical Oncology and HPB Program at Piedmont. Last week we were honored by a transformational gift to create the Sherron Berg Early Detection Pancreatic Cancer Program, and I am humbled to now be the Sherron Berg Medical Director. Our team will continue to work towards earlier detection and access to research - with the shared vision for more cures from pancreatic cancer."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 72 | - | - | ||
| 6 250 | - | - | ||
| 185 | - | - | ||
| 76 243 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 214 715 | 3 214 715 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 214 715 | 3 214 715 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
21 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · Muokattu@Micketro (Krosen on Placera-forum) If Jeff achieves what he believes about March-April and that the 50 states are ready to receive the test, then we should see a short rally, right, before new financing challenges arise? Remember also that there will probably be a small share price boost perhaps just from the announcement that the application to Medicare has been submitted this summer. If they manage to hurry up and convince a partner to step a bit deeper before time. That could really be what we need with this stock. But such things are very uncertain regarding a partner.. Do you think they'll fix that with a bridge loan, or partnership? There's probably little point with a NE for such a small amount. Investors will surely flee if there are too many NEs in a row, those are my thoughts on it. I see you're commenting on a guessed amount: https://forum.placera.se/inlagg/1be7359a-7527-4edb-ad12-72992b3e89da·21 t sitten · MuokattuI actually don't know how they will raise the money, even though NE is the only thing they have used historically. The post was just an estimate of how much money is missing when one accounts for carlsquares sales forecasts. Here one must assume that all sales in New York etc are already included. They need to raise 100 million before q4 this year if one trusts Carlsquares figures, if they are to make it to 2027
- ·13.3. · MuokattuAll-time low today. I have gone long in this stock with relatively small capital. It is either a stock that will be quickly revalued when it happens, because the product is good and needs to be established in the market. If this doesn't happen, I think it will be difficult for the company to survive.·20 t sittenGood product, but low demand due to insufficient marketing.·11 t sittenI think it's the opposite, actually. They have invested heavily in close contact with many test centers, and have pushed hard on the marketing side. But the product itself is something that doesn't have an obvious place in a clinical workflow, and work is needed from the client side to figure out how to use it.
- ·13.3.A little positive general treatment development, cancer treatment in Tromsø, Norway. Imagine if the headline was as one read it. Which it isn't. It is the radiation that is the radioactive missiles they are talking about, and not radioactive material from war materiel (my thoughts did go a bit to Iranian uranium, I must admit 🙈). https://www.nrk.no/tromsogfinnmark/forskere-ved-uit-og-unn-skal-bruke-_radioaktive-missiler_-mot-alvorlig-kreft-1.17804026 Subsequently, doctors can send a more powerful type of radioactive substance to the same cells. – We use a carrier molecule that recognizes special characteristics of cancer cells. It transports the radiation directly to them and kills the cancer cells without damaging the surrounding tissue, explains Sundset. The treatment is particularly aimed at patients where other forms of treatment no longer work. According to Sundset, cancer cells can eventually become resistant to treatments such as chemotherapy, radiation, and immunotherapy.
- ·13.3.Risk index predicts pancreatic neuroendocrine tumor recurrence Translated from Israeli Text is behind a registration wall (you who are medical personnel). Still a somewhat interesting headline https://www.e-med.co.il/specialties/oncology/2026/03/12/601301 Source: JAMA Surgery Prof. Amit Akirov 12/03/2026 No comments Risk index based on four factors – male gender, tumor size, grade according to the World Health Organization classification, and lymphovascular
- ·13.3.Does anyone know if Immunovia/ PancreaSure is involved in this great news from Piedmont? https://www.linkedin.com/posts/andrew-page-md-193622106_our-team-is-indebted-to-many-donors-and-supporters-activity-7435783495425126401-x-oc "Our team is indebted to many donors and supporters of the Surgical Oncology and HPB Program at Piedmont. Last week we were honored by a transformational gift to create the Sherron Berg Early Detection Pancreatic Cancer Program, and I am humbled to now be the Sherron Berg Medical Director. Our team will continue to work towards earlier detection and access to research - with the shared vision for more cures from pancreatic cancer."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 72 | - | - | ||
| 6 250 | - | - | ||
| 185 | - | - | ||
| 76 243 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 214 715 | 3 214 715 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 214 715 | 3 214 715 | 0 | 0 |